SRP4966

VEGI/TNFSF-15 human

recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)

• Synonym(s): TNFSF15, VEGI isoform, VEGI192A, Vascular Endothelial Growth Inhibitor
• UNSPSC Code: 12352200
• NACRES: NA.32

Properties

• biological source: human
• recombinant: expressed in E. coli
• assay: ≥95% (HPLC); ≥95% (SDS-PAGE)
• form: lyophilized
• mol wt: ~21.8 kDa
• packaging: pkg of 10 μg
• storage condition: avoid repeated freeze/thaw cycles
• impurities: endotoxin, tested
• NCBI accession no.: AAR98573
• UniProt accession no.: O95150
• shipped in: wet ice
• storage temp.: −20°C
• Gene Information: human ... TNFSF15(41019336)

Description

General description

VEGI (Vascular Endothelial Growth Inhibitor) is a member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities of endothelial cells: early Gl arrest of G0/G1-cells responding to growth stimuli, and programmed cell death. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. Human VEGF is a 21.8 kDa homodimeric protein consisting of 192 amino acid polypeptide chains.

Physical form

Lyophilized from a solution containing 0.5 M NaCl, 50 mM Tris-HCl, pH 7.5.

Reconstitution

Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.

Reconstitute in water to a concentration of 0.1–1.0 mg/mL. This solution can then be diluted into other aqueous buffers.